Kandasamy Ramasamy

6423695, Jul 23, 2002

Dec 20, 1999

09/467443

Robert Tam - Irvine CA
Guangyi Wang - Irvine CA
Devron Averett - Irvine CA
Kandasamy Ramasamy - Laguna Hills CA

Ribapharm, Inc. - Costa Mesa CA

A61K 31675

514 81

Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patients GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response. Controlled release dosage forms are particularly contemplated to achieve that result.

6552183, Apr 22, 2003

Aug 7, 2000

09/633493

Kandasamy Ramasamy - Laguna Hills CA
Robert Tam - Irvine CA
Devron Averett - Irvine CA

ICN Pharmaceuticals, Inc. - Costa Mesa CA

C07H 19044

536 286, 536 287, 536 288, 514 43

Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.

6573248, Jun 3, 2003

Dec 31, 2001

09/969355

Kandasamy Ramasamy - Laguna Hills CA
Robert Tam - Irvine CA
Devron Averett - Irvine CA

ICN Pharmaceuticals, Inc. - Costa Mesa CA

A61K 3170

514 43, 536 286, 536 287, 536 288, 544224, 5462521, 546255, 5463001, 5463561, 546400

Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.

6613896, Sep 2, 2003

Jun 6, 2000

09/445713

Kandasamy Ramasamy - Laguna Hills CA
Rajanikanth Bandaru - Irvine CA
Devron Averett - Irvine CA

ICN Pharmaceuticals, Inc. - Costa Mesa CA

C07H 706

536 292, 536 187, 514 23, 514183, 514359, 514360

C-nucleosides are synthesized by a method in which a sugar is derivatized in a single step to provide a heterocycle at the C position, and then the heterocycle is aromatized in another single step. In one class of preferred embodiments a cyano sugar is converted into thiocarboxamide, and subsequently condensed to form an azole ring. In a second class of preferred embodiments a cyano sugar is condensed with an amino acid to provide the azole ring. In a third class of preferred embodiments a halo sugar is condensed with a preformed heterocycle to provide the azole ring.

7638496, Dec 29, 2009

Aug 22, 2002

10/227235

Robert Tam - Irvine CA, US
Kandasamy Ramasamy - Aliso Viejo CA, US
Zhi Hong - Aliso Viejo CA, US
Johnson Lau - Newport Beach CA, US

Valeant Pharmaceuticals North America - Aliso Viejo CA

A01N 43/04
A61K 31/70

514 43, 514 44, 514 45, 536 269, 536 272

Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.

20020132784, Sep 19, 2002

Apr 29, 2002

10/136745

Robert Tam - Irvine CA, US
Guangyi Wang - Irvine CA, US
Devron Averett - Irvine CA, US
Kandasamy Ramasamy - Laguna Hills CA, US

A61K031/7052
A61K031/4196

514/043000, 514/383000

Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patient's GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response. Controlled release dosage forms are particularly contemplated to achieve that result.

20030207826, Nov 6, 2003

Apr 30, 2003

10/428806

Robert Tam - Irvine CA, US
Guangyi Wang - Irvine CA, US
Devron Averett - Irvine CA, US
Kandasamy Ramasamy - Laguna Hills CA, US

A61K031/7056
A61K031/675
A61K031/4196

514/043000, 514/081000, 514/383000

Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another, aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patient's GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response. Controlled release dosage forms are particularly contemplated to achieve that result.

59691352, Oct 19, 1999

Nov 2, 1995

8/551947

Kandasamy Ramasamy - Laguna Hills CA
Wilfried E. Seifert - La Jolla CA

ICN Pharmaceuticals, Inc. - Costa Mesa CA

C07D47300
C07F 902

544264

The present invention provides various novel oligonucleotide analogs having one or more properties that make the subject compounds superior to conventional oligonucleotides for use in procedures employing oligonucleotides. The compounds of the invention are oligonucleotide analogs in which the furanose ring of a naturally occurring nucleic acid is replaced with an amino acid or a modified amino alcohol residue. Some embodiments of the novel compounds of the invention are particularly useful for the antisense control of gene expression. The compounds of the invention may also be used as nucleic acid hybridization probes or as primers. Another aspect of the invention is to provide monomeric precursors of the oligonucleotide analogs of the invention. These monomeric precursors may be used to synthesize the subject polynucleotide analogs. Another aspect of the invention is to provide formulations of the subject polynucleotide analogs that are designed for the treatment or prevention of disease conditions.